STOCK TITAN

Veradermics, Incorporated (MANE) Stock Price, News & Analysis

MANE NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
56 197 sessions, February 4, 2026 to November 13, 2026
Largest daily move
+47.6% close of April 27, 2026
1-month change
+11.5% closing prices, October 13, 2026 to November 13, 2026

Company Description

Veradermics (MANE) Company Overview

Veradermics, Incorporated is a dermatologist-founded, late-stage biopharmaceutical company focused on developing therapeutics for pattern hair loss, also known as androgenetic alopecia. The company trades on the NYSE under the symbol MANE and is based in New Haven, Connecticut. Its work sits at the intersection of biopharmaceutical drug development, aesthetic dermatology, and hair-loss treatment.

Veradermics’ lead program is VDPHL01, a proprietary investigational oral, non-hormonal, extended-release minoxidil tablet being developed for pattern hair loss in both women and men. The company describes VDPHL01 as a minoxidil product that uses extended-release technology and a gel matrix designed to provide long-lasting, steady release for sustained absorption. That formulation approach is central to the company’s development strategy because Veradermics is seeking to address treatment barriers in chronic hair-loss therapy through an oral product candidate rather than a topical product.

The company’s public materials focus on clinical development rather than commercial product marketing. VDPHL01 remains investigational, and Veradermics’ disclosures describe clinical studies evaluating safety, tolerability, efficacy, onset of activity, treatment response, and hair-count outcomes in patients with mild-to-moderate pattern hair loss. The program includes studies in both male and female patients, with late-stage and registration-directed trial activity forming the core of the company’s business profile.

Business Focus and Development Model

Veradermics operates as a clinical-stage biopharmaceutical company, which means its central work is to develop drug candidates through clinical trials and regulatory pathways. The company has described its broader aim as building a focused portfolio of aesthetic dermatology product candidates targeting high-prevalence dermatologic conditions, with potential selective development of medical dermatology product candidates.

The company reports that it operates in a single segment for allocating resources, assessing performance, and making operating decisions. That structure fits a company centered on one lead development program and a focused dermatology pipeline, rather than a business split across multiple commercial product lines or operating subsidiaries.

For investors researching MANE stock, the key business question is not a conventional product-sales mix. The core issue is how Veradermics advances VDPHL01 through clinical development, how study results support or limit the program, and how future regulatory filings may define the product candidate’s path. Company updates often emphasize trial design, patient populations, efficacy and safety data, and the potential role of an oral non-hormonal option in pattern hair loss.

Lead Program: VDPHL01

VDPHL01 is the company’s main disclosed product candidate. Veradermics describes it as a proprietary extended-release oral minoxidil formulation. The company has stated that the formulation is designed to avoid the high peak concentrations of immediate-release oral minoxidil while extending time above the minimum hair-growth threshold.

The program is being evaluated in pattern hair loss, including female pattern hair loss and male pattern hair loss. Veradermics’ disclosures describe trial work in patients with mild-to-moderate disease and include open-label, randomized, double-blind, placebo-controlled, Phase 2, Phase 2/3, and Phase 3 study designs. These trial types matter because they generate the clinical evidence used to assess whether an investigational therapy shows a favorable balance of efficacy, safety, and tolerability.

Because VDPHL01 is still described as investigational, its value to the company depends on clinical and regulatory progress. Investors commonly review topline data, subgroup analyses, safety disclosures, trial enrollment status, and registration-directed study updates when evaluating a clinical-stage biopharmaceutical company such as Veradermics.

Pattern Hair Loss and Dermatology Context

Pattern hair loss, also called androgenetic alopecia, is the condition targeted by Veradermics’ lead program. Company materials describe the condition as common among both women and men and note that it can affect quality of life, including mental health, self-esteem, relationships, and social activity.

Veradermics’ focus on pattern hair loss places the company within aesthetic dermatology, a field that includes treatments aimed at visible dermatologic concerns. The company has also stated that it may selectively develop medical dermatology product candidates. Based on its disclosures, however, VDPHL01 and pattern hair loss are the primary identity of the company.

The company’s dermatologist-founded background is relevant because its disclosed product strategy is built around dermatologic conditions and trial programs involving patients with hair-loss disease. Its communications frequently use dermatology-specific terms such as target area hair count, investigator global assessment, patient-reported outcomes, and androgenetic alopecia.

What Makes Veradermics Distinct

Veradermics is distinct from many broader biotechnology companies because its disclosed identity is tightly tied to dermatology and pattern hair loss. The company is not presented as a multi-therapeutic-area drug developer. Instead, its public profile centers on one lead oral minoxidil formulation and a focused aesthetic dermatology strategy.

  • Dermatology focus: Veradermics is built around aesthetic dermatology and high-prevalence dermatologic conditions.
  • Lead oral candidate: VDPHL01 is an investigational oral, non-hormonal, extended-release minoxidil tablet.
  • Male and female development: The company is evaluating VDPHL01 for pattern hair loss in both women and men.
  • Late-stage clinical profile: Veradermics describes itself as late-stage and late clinical-stage, with VDPHL01 in advanced clinical development.
  • Single operating segment: The company reports one segment for resource allocation and performance assessment.

Key Points for MANE Stock Research

Research on Veradermics stock usually centers on clinical evidence, regulatory progress, financing activity, and the company’s ability to support its development program. Since Veradermics is a clinical-stage biopharmaceutical issuer, periodic filings and material-event reports can be especially important. These disclosures document trial updates, securities offerings, equity plans, marketable securities, stock-based compensation, and other items relevant to a company developing investigational therapeutics.

Veradermics’ public-company record includes IPO registration materials, quarterly reports, and 8-K filings tied to financial results, clinical data, public offerings, and Regulation FD disclosures. Those filings are useful because they provide the formal record behind company news releases and investor presentations.

Stock Performance

$128.30
-1.05%
-1.36
After hoursChange vs the $129.66 closeLast updated: November 13, 2026 at 18:39
+11.5%
Performance 1 month

Veradermics, Incorporated (MANE) closed at $129.66 on November 13, 2026. Over the past month, the price has gained 11.5%.

See what a $1,000 investment in MANE would be worth today

Average down calculator for MANE

MANE Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Veradermics, Incorporated has 10 recent news articles, with the latest published 3 days ago. Of the recent coverage, 8 articles coincided with positive price movement and 1 with negative movement. Key topics include earnings, clinical trial, conferences. View all MANE news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
1,250,000
Shares Sold
4
Transactions
Most Recent Transaction
ENRIGHT PATRICK G (Director) sold 500,000 shares held indirectly at an average of $150.38 on November 11, 2026

Insider selling at Veradermics, Incorporated over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Veradermics, Incorporated reported operating income of -$72.3M in FY2025, and net income was -$70.0M. Diluted earnings per share stood at -$111.91. The company generated -$71.6M in operating cash flow. The current ratio was 16.66, measuring current assets divided by current liabilities.

-$70.0M
Net Income (FY2025)
-$71.6M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

NOV
19
November 19, 2026 Marketing

Jefferies Healthcare Presentation

Management presenting at Jefferies Global Healthcare Conference in London; live webcast at ir.veradermics.com, replay ~30 days.
H1
2027
H1 2027 Clinical

Study 306 topline results

Veradermics expects female Phase 3 Study 306 topline results in H1 2027; timing may include press release and investor webcast.
H1
2027
H1 2027 Clinical

Study 306 Results

Topline results for female Study 306 of oral VDPHL01 expected in H1 2027; pivotal Phase 3 data may affect regulatory path and valuation.
H1
2027
H1 2027 Clinical

Female trials topline data

Topline data for female trials 207 and 306 expected through 1H 2027 (Jan–Jun); results will inform regulatory strategy.
H1
2027
H1 2027 Clinical

Study 306 data release

Veradermics expects female Study 306 VDPHL01 data to be reported in H1 2027; timing may include press release and webcast.
H1
2027
H1 2027 Clinical

Study 306 topline data

Topline data expected for Phase 2/3 Study 306 of VDPHL01 in women with pattern hair loss; results due 1H 2027.

Veradermics, Incorporated has 6 upcoming scheduled events. The next event, "Jefferies Healthcare Presentation", is scheduled for November 19, 2026 (in 4 days). Investors can track these dates to stay informed about potential catalysts that may affect the MANE stock price.

Short Interest History

Last 12 Months

Short interest in Veradermics, Incorporated (MANE) currently stands at 3.4 million shares, down 8.4% from the previous reporting period, representing 8.7% of the float. Since February 2026, short interest has increased by 227.8%.

Days to Cover History

Last 12 Months

Days to cover for Veradermics, Incorporated (MANE) currently stands at 5.1 days, up 34.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since February 2026, the figure has increased by 195.9%. Across the settlements charted above, it has ranged from 1.7 to 7.5 days.

MANE Company Profile & Sector Positioning

Veradermics, Incorporated (MANE) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NYSE.

Investors comparing MANE often look at related companies in the same sector, including Scholar Rock Holding Corporation (SRRK), Erasca, Inc. (ERAS), PTC Therapeutics, Inc. (PTCT), Edgewise Therapeutics, Inc. (EWTX), and Ligand Pharmaceuticals Inc. (LGND). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MANE's relative position within its industry.

Frequently Asked Questions

The current stock price of Veradermics, Incorporated (MANE) is $128.30 in after-hours trading as of November 13, 2026.

The market cap of Veradermics, Incorporated (MANE) is approximately $5.4B. Learn more about what market capitalization means .

The FY2025 net income of Veradermics, Incorporated (MANE) is -$70.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Veradermics, Incorporated (MANE) is -$111.91 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Veradermics, Incorporated (MANE) is -$71.6M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Veradermics, Incorporated (MANE), current assets divided by current liabilities, was 16.66 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Veradermics, Incorporated (MANE) is -$72.3M for FY2025, its most recent completed fiscal year. Learn about operating income.

Veradermics is a dermatologist-founded, late-stage biopharmaceutical company focused on developing therapeutics for pattern hair loss. Its disclosed strategy also includes a focused portfolio of aesthetic dermatology product candidates targeting high-prevalence dermatologic conditions.

VDPHL01 is Veradermics’ proprietary investigational oral, non-hormonal, extended-release minoxidil tablet. The company is developing it for pattern hair loss in both women and men.

Veradermics’ lead program targets pattern hair loss, also known as androgenetic alopecia. Company materials describe development work in both female and male pattern hair loss.

Veradermics describes VDPHL01 as an investigational drug in clinical development. The company’s disclosures discuss clinical studies and potential regulatory approval rather than an approved marketed product.

Veradermics describes VDPHL01 as an extended-release oral minoxidil formulation. The formulation uses a gel matrix designed to provide long-lasting, steady release for sustained absorption.

Veradermics is based in New Haven, Connecticut. Its common stock trades on the NYSE under the symbol MANE.

The company has described its operations as a single segment for allocating resources, assessing performance, and making operating decisions. Its public profile is centered on dermatology drug development.

Veradermics has disclosed clinical work involving Phase 2, Phase 2/3, and Phase 3 studies of VDPHL01. Its trial disclosures include evaluation of safety, efficacy, tolerability, onset of activity, and hair-growth outcomes.